Study identification

PURI

https://redirect.ema.europa.eu/resource/106492

EU PAS number

EUPAS106491

Study ID

106492

Official title and acronym

Patient characteristics and treatment pathways in patients with COPD initiated on ICS/LABA/LAMA and LABA/LAMA treatment

DARWIN EU® study

No

Study countries

United Kingdom

Study description

A historical cohort study to describe patient characteristics and 5-year treatment pathways prior to initiation on ICS/LABA/LAMA (triple therapy) and LABA/LAMA (dual bronchodilator) therapy in real-world clinical settings in the United Kingdom

Study status

Planned
Research institutions and networks

Institutions

Networks

Contact details

David Price

Primary lead investigator
Study timelines

Date when funding contract was signed

Planned:

Study start date

Planned:

Date of final study report

Planned:
Sources of funding
Other
Pharmaceutical company and other private sector 

More details on funding

Chiesi Pharma, OPRI
Regulatory

Was the study required by a regulatory body?

No

Is the study required by a Risk Management Plan (RMP)?

Not applicable